The Suppressed Record: What the FDA Files Actually Show About Antidepressants

How Psychiatric Drugs were sold as Effective

A documentary on YouTube titled: How Psychiatric Drugs were sold as Effective

What you are about to read has taken me months to write. I was reluctant to publish it as I do not think this report is comprehensive enough as it is. I have several hundreds of pages of personal and shared notes on this subject. In full disclosure; this article is the watered down version of what I wanted to publish. I need people to read my report, it’s been my experience that most folks don’t like nor appreciate the “extreme” version of reality.-MK3

For decades, American doctors were trained on a version of psychiatric drug data that had been filtered, reframed, and in some cases ghostwritten. The full record tells a different story.

What the FDA Actually Received

When a pharmaceutical company seeks approval for a psychiatric drug, it submits complete clinical trial data to the FDA. Not summaries. Not press releases. The raw results. These are documents the public almost never sees.

In the late 1990s, psychologist Irving Kirsch used the Freedom of Information Act to obtain the FDA’s complete trial records for the most widely prescribed antidepressants in America: Prozac, Paxil, Zoloft, Celexa, and Effexor. What he found was not what doctors were being taught.

Approximately half of submitted antidepressant trials failed to show benefit over placebo. The average drug-placebo difference on depression rating scales measured 1.8 points, well below the 3-point threshold considered clinically perceptible. Between 75 and 80 percent of improvement observed in trials occurred in the placebo group, not the drug group.

The FDA reviewers noticed. On Paxil, an FDA medical reviewer wrote that the drug showed minimal improvement over placebo. On Prozac, an FDA statistical review noted the clinical significance of the observed difference was questionable. On Celexa, a reviewer wrote the effect size is small.

That language exists in the approval documents. It was not transmitted to medical schools.

Many trials failed. Average benefits were small. Placebo did most of the work. Clinical relevance was questioned by FDA scientists themselves. And yet doctors were taught that antidepressants correct a chemical imbalance in the brain. These two positions cannot coexist. One of them was manufactured.

Study 329: A Case Study in What Went Wrong

In 1998, GlaxoSmithKline completed a clinical trial testing Paxil in adolescents. The trial number was 329. The data was unambiguous: the drug failed to outperform placebo on its primary measures, and adolescents on Paxil experienced significantly higher rates of suicidal thoughts and attempts.

When Study 329 was published in a major medical journal in 2001, it concluded that Paxil was “generally well tolerated and effective.” To reach that conclusion, the authors changed the outcome measures after the trial ended, reclassified suicidal behavior as “emotional lability,” and minimized adverse events. The paper was not written by the listed academic authors. It was ghostwritten by a medical communications firm working for GlaxoSmithKline.

Internal company documents, released years later through litigation, showed GSK executives knew the trial had failed. One memo described the study as “insufficiently positive.” Another warned that publishing the raw findings would be “commercially unacceptable.”

For years after publication, Paxil was prescribed to adolescents based on Study 329. No warning accompanied those prescriptions. The study was not corrected by peer review or by regulators. It came to light through lawsuits and a reanalysis that reached the opposite conclusion.

The Same Pattern, Repeated

Study 329 was not an outlier. When researchers compared the FDA’s complete trial records against the published medical literature, the pattern held consistently across drugs and manufacturers.

Pfizer conducted multiple pediatric trials on Zoloft. Several failed to show efficacy. The published literature emphasized benefit. Forest Laboratories’ adolescent trial for Celexa failed its pre-specified primary outcomes. The company reframed secondary measures and published the study as positive. Court records confirmed Forest knew the trial had failed.

A 2008 analysis published in the New England Journal of Medicine found that across antidepressant trials submitted to the FDA, nearly half were negative. Yet over 90 percent of published papers reported positive results. A 2015 analysis published in JAMA Psychiatry confirmed that reporting biases led to significant increases in the number of positive findings appearing in the medical literature. The evidence base that trained a generation of psychiatrists was not incomplete by accident. It had been curated.

The Risk Profile That Was Not Disclosed

The incomplete efficacy record represents only one part of what patients were not told. Peer-reviewed research, much of it published in major journals, documents a range of serious adverse effects that were systematically underreported in clinical trial literature.

A 2016 meta-analysis in European Neuropsychopharmacology found significant bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety. The risks that were tracked but not prominently reported include the following.

Cardiovascular and metabolic effects. Antidepressant use has been associated with elevated fasting plasma glucose concentrations, hypertension, and low HDL-cholesterol, according to research published in BMC Public Health. A meta-analysis in Diabetologia found that antidepressant users have a moderately elevated risk of type 2 diabetes mellitus compared with non-users, even after adjustment for body mass index. SSRIs and SNRIs were associated with increased type 2 diabetes risk in a 2017 study published in JAMA Pediatrics. Research published in Psychosomatic Medicine found that in depressed monkeys treated with sertraline, coronary artery atherosclerosis was 4.9 times higher than in untreated depressed monkeys. The combined use of antidiabetic and antidepressant drugs was associated with a higher risk of myocardial infarction compared with use of either drug group alone, according to a 2015 study in Diabetic Medicine.

Neurological and cognitive effects. A meta-analysis published in Depression and Anxiety found that antidepressant drug usage is associated with higher odds of Alzheimer’s disease and dementia. A 2019 study in the American Journal of Geriatric Psychiatry found that monotherapeutic antidepressant exposure in old age was associated with increased incident dementia. In older populations, SSRI and SNRI use has been linked to increased risk of hemorrhagic stroke, per a 2019 study in Drug Safety. A BMJ study found that antidepressant use in populations aged 65 or older is associated with adverse outcomes including higher all-cause mortality.

Reproductive and developmental effects. Antidepressants have been associated with birth defects across multiple human studies, including congenital heart defects. A 2016 study in JAMA Pediatrics found that SSRI use during the second or third trimester increases the risk of autism spectrum disorder in children. SSRI use in the second half of pregnancy was associated with risk of persistent pulmonary hypertension in newborns. Women exposed to antidepressant and anxiolytic medication before the 16th week of pregnancy carry a threefold increased risk for preeclampsia, according to a 2019 study in BMC Pregnancy and Childbirth. Prenatal SSRI exposure has been shown in animal studies to induce working memory and social recognition deficits in offspring. Fluoxetine treatment of male rats produced long-term adverse effects on fertility and reproductive function.

Suicidality and psychiatric destabilization. Research published in Archives of General Psychiatry found that current antidepressant use among suicidal subjects was associated with a markedly increased risk of attempted suicide. A 2017 study in Pharmacopsychiatry found that participants taking antipsychotics were 1.70 times more likely to complete suicide compared with those who did not. Antidepressants have been associated with antidepressant-induced manic or hypomanic switch in a large proportion of bipolar disorder patients. Unipolar depression treated with antidepressants is associated with increased risk of subsequent mania and bipolar disorder diagnosis, according to a 2015 study in BMJ Open.

Systemic effects. Fluoxetine has been shown to reduce thyroid hormone levels in patients with normal thyroid function, with reductions in T3 and T4 recorded after 15 and 30 days of treatment. Paroxetine treatment resulted in significant reduction of thyroxine in depressed patients, with antidepressants classified as endocrine disruptors in published research. SSRIs increase the risk of excessive bleeding following trauma, with pre-injury SSRI use associated with higher blood transfusion requirements after solid organ injury. Multiple antidepressants have been associated with antibiotic resistance: fluoxetine has been shown to induce multiple antibiotic resistance in E. coli through reactive oxygen species-mediated mutagenesis.

The Industry’s Role in Medical Education

Between 2009 and 2013, GlaxoSmithKline, Pfizer, Eli Lilly, Janssen, and Forest Laboratories collectively paid more than nine billion dollars to resolve federal fraud charges related to the marketing of psychiatric medications. Charges included illegal promotion to children, suppression of safety data, and payments to physicians for off-label promotion.

The payments resolved legal liability. They did not revise a single medical school curriculum. Yes, this means this is all still going on in the industry today. They show NO signs of changing it.

Internal documents released through those proceedings showed that pharmaceutical companies funded ghostwritten journal articles, prepared continuing medical education slide decks, and recruited academic psychiatrists to attach their names as authors. One internal planning document described the objective as driving key messages into medical education. Universities relied on those journals, those programs, and those guidelines. The professors who taught from them were not, for the most part, knowingly complicit. They were downstream of a system that had already been shaped before they entered the room.

Long-Term Outcomes: What the Data Showed

By the early 2000s, psychiatric disability was rising. Not despite expanded drug treatment, but alongside it. According to Social Security Administration data, Americans receiving federal disability benefits for mental illness tripled between 1987 and 2007, from roughly 1.25 million to more than 4 million. That increase occurred during the greatest expansion of psychiatric prescribing in history.

Psychiatrist Martin Harrow at the University of Illinois followed schizophrenia patients for 20 years. His findings were consistent: patients who remained on antipsychotic medication long-term were far more likely to remain psychotic and disabled than patients who discontinued under careful supervision. The World Health Organization’s large international schizophrenia studies found similar patterns. Patients in lower-income countries, where antipsychotics were used more sparingly, had substantially better long-term outcomes.

These findings did not change the curriculum.

Between 1996 and 2007, the proportion of doctor visits at which antidepressants were prescribed without any accompanying psychiatric diagnosis increased from 59.5 percent to 72.7 percent, according to research published in Health Affairs. Drugs originally approved for specific diagnosed conditions were being deployed across the general population without the clinical basis that even the original approval process had required.

What the Evidence Shows About Alternatives

The published research documenting harm from antidepressants exists alongside a separate body of evidence showing that alternatives frequently perform comparably, and in some cases outperform pharmaceutical treatment.

Multiple randomized controlled trials have found that St. John’s Wort performs comparably or superiorly to fluoxetine in mild to moderate depression. Saffron has demonstrated antidepressant efficacy comparable to fluoxetine across multiple human studies, with a more favorable side effect profile. Rhodiola rosea, while somewhat less effective than sertraline in one comparative study, demonstrated a more favorable risk-to-benefit ratio. Light therapy, both as monotherapy and in combination with fluoxetine, was found efficacious and well tolerated for non-seasonal major depressive disorder in a study published in JAMA Psychiatry. Aerobic exercise has demonstrated value as a complementary therapy. Acupuncture has outperformed Prozac on long-term depression outcomes in multiple published trials.

These are not alternative medicine claims. They are findings from peer-reviewed research indexed in PubMed and published in mainstream journals. They were available. They were and still are largely not taught.

What This Means

This is not a claim that psychiatric drugs never help anyone. Short-term symptom relief is real and, for some people in acute crisis, genuinely important. The problem is narrower and more serious: what patients and doctors were told about how these drugs work, how effective they are, and what the long-term consequences look like was not derived from the complete evidence. It was derived from a curated version of it.

More than 60 million Americans are currently taking at least one psychiatric medication. Over 4 million children are prescribed psychiatric drugs. The FDA’s own reviewers questioned the clinical significance of the effects they were and still are approving. That language existed in the files. It was not transmitted.

The full record was available. Through FOIA requests, through litigation discovery, through independent reanalysis. What it shows is not a story of a few bad actors or isolated failures. It is a story of systematic curation, from trial design through journal publication through medical education, that produced a version of the evidence base doctors were trained on that did not match the underlying data.

That is the record. It stands on its own.

Resources:

On PubMed there is a library of over 10,000 study and research papers or articles tagged with Antidepressants Research

GreenMedinfo has over 160 abstracts tagged with Antidepressants Research

Watch the documentary from The Health Briefing on YouTube

© 2026 – MK3 Law Group

For republication or citation, please credit this article with link attribution to MarginOfTheLaw.com.